|
|||||
|
|
Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand,Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events |
|
| Authors: | H. Hamzeh-Cognasse S. Laradi J. C. Osselaer F. Cognasse O. Garraud |
| Affiliation: | 1. Université de Lyon, GIMAP-EA3064, Saint Etienne, France;2. Université de Lyon, GIMAP-EA3064, Saint Etienne, France EFS Auvergne-Loire, Saint Etienne, France;3. Service régional vaudois de transfusion sanguine, Epalinges, Switzerland;4. Université de Lyon, GIMAP-EA3064, Saint Etienne, France Institut National de Transfusion Sanguine (INTS), Paris, France Correspondence: Olivier Garraud, INTS and GIMAP-EA 3064, Université de Saint-Etienne, Faculté de Médecine, 15 rue Ambroise Paré, 42023 Saint-Etienne Cedex 2, France |
| Abstract: | Platelets in therapeutic platelet concentrates are commonly acknowledged to release biologically active constituents during storage. This study examined the influence of photochemical pathogen reduction treatment (PRT) using amotosalen-HCl and UVA light vs. untreated control platelet components, on three factors recently reported to be associated with serious adverse events associated with platelet component (PC) transfusions: sCD40L, IL-27 and sOX40 ligand. Levels of such cytokine-like factors increased significantly during storage, but no significant difference was detected between PRT- and control PCs. This suggests that occurrences of AEs are not directly influenced by PRT but rather may depend on alternate determinants. |
| Keywords: | cytokine inflammation pathogen reduction treatment platelet storage |